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Tamoxifen induces lymphatic vessels disruption and 
promotes lymphedema.  
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2/ Tamoxifen and Estradiol promote lymphangiogenesis  
in lymphedema by inducing hyaluronan synthesis 
5/ Tamoxifen inhibits estradiol-induced migration and 
tubulogenesis  in HDLEC 
Whole-mount LYVE-1 staining shows lymphatic disruption in tamoxifen-treated mice trachea [A-G] 
and diaphragm [I-K], two organs highly vascularised by lymphatics. Tamoxifen inhibits the formation 
of branch points and filopodia [D-L] and disorganizes the structure of the lymphatic network. 
In vitro, tamoxifen inhibits Estradiol-induced tubulogenesis [A-D, I], filopodia formation [E-H] and 
migration [J] but has no effect on survival [K]. 
To induce  secondary lymphedema, we designed a mice model where we performed a skin flap surgery 
associated with axillary and brachial lymph nodes dissection [A] . Two weeks after surgery we observed 
an increase of leg size [B]. As observed in control skins, both treatments promote skin 
lymphangiogenesis [C-F]. Estradiol and tamoxifen both induce hyaluronic acid synthesis 
3/ Tamoxifen impairs lymphatic drainage in lymphedema 
To identify the physiological effects of 17β estradiol and tamoxifen treatments, we performed LYVE-1 
immunostaining and lymphangiography in control skins [A-D]. We demonstrated that both treatments 
promote skin lymphangiogenesis but tamoxifen modify the structure of lymphatic capilaries. Interestingly, 
despite this disruption, the lymphatic drainage is still  functional [E-H]. 






Tamoxifen : A risk factor for lymphedema 
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Branch points trachea Branch points diaphragm Filopodia trachea 
I K Tubulogenesis Migration Survival 
More than 10 percent of breast cancer survivors develop secondary lymphedema within weeks and months after surgery and radiotherapy. Lymphedema refers to a condition of lymphatic dysfunction, which results in a massive fluid and fat accumulation. Although it is a common 
disabling disease causing significant morbidity, treatment for this chronic pathology remains limited and largely ineffective consisting in massage, restrictive bandaging and dietary restrictions.  
This study aim to demonstrate that lymphedema is a complex pathophysiological process rather than a surgical side effect. We evaluated the effect of tamoxifen, the major treatment for breast cancer, in promoting lymphedema. We found that tamoxifen disrupts normal skin drainage 
and leads to lymphatic leakage. It destabilizes lymphatic network and reduces number of lymphatic endothelial cells filopodia, but has no effect on skin lymphatic density. To mimic the effect of human therapies, we developed a model of mice secondary lymphedema induced by 
mastectomy associated to axillary lymph nodes dissection. In this model, tamoxifen inhibits lymphatic healing by targeting both lymphatic endothelium and subcutaneous adipose tissue lymphangiogenic growth factor synthesis.  
In conclusion, this study demonstrates for the first time the crucial effect of the main drug of breast cancer patients, tamoxifen on lymphatic function. Our work should thus bring new insights for a better understanding on the lymphedema prevalence and constitute a first step to the 
treatment of secondary lymphedema. 
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4/ Tamoxifen disrupts lymphatic network by inhibiting 
filopodia formation 
1/ Tamoxifen is an agonist of Estradiol in promoting 
lymphangiogenesis but disrupts lymphatic drainage 
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